NASDAQ$SCYX
Scynexis Inc · Q2 2026 earnings
Q2 2026 earnings · · After market close · Investor relations
Briefing
Scynexis Inc reported net income of $7.4 million for Q2 2026 driven by warrant liability gains.
SCYNEXIS posted license revenue of $0.2 million and swung to net income of $7.4 million from a $6.9 million loss a year earlier, primarily due to a $14.2 million warrant liability fair value gain. Operating expenses fell to $8.0 million while the company advanced its SCY-770 ADPKD program after the Poxel acquisition. Cash and investments totaled $71.1 million, providing runway into 2029.
- Q2 net income reached $7.4 million versus a $6.9 million loss in Q2 2025, fueled by $14.2 million in warrant gains.
- License revenue declined to $0.2 million from $1.4 million year-over-year.
- R&D expenses dropped 46% to $3.9 million as MARIO study costs wound down.
- Balance sheet strengthened with $71.1 million in cash and investments after March 2026 private placement.
Headline financials
Revenue & EPS history
Scynexis · Revenue · Quarterly
$235K
Revenue by segment
Scynexis · $235K total across 1 segment · Q2 2026
- License agreement revenue$235K—100.0%
Forward guidance
Company plans Phase 2 SCY-770 study initiation in Q4 2026 with efficacy readout in H2 2027 and anticipates SCY-247 Phase 2 in H1 2027.
Tailwinds
- Cash runway extended into 2029 post-financing
- Potential $146 million GSK milestones plus royalties
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports
+12.3%
Avg return
Earnings day
+14.8%
Avg return
5 days after
+10.7%
Avg return
30 days after
53%
28 / 53 earnings
Positive
+619.7%
Q1 2026
Best reaction
-38.9%
Q1 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | +619.7% | +546.3% | +353.1% | |
| Q4 2025 | +2.9% | +16.1% | +14.6% | |
| Q3 2025 | -5.6% | -4.8% | +4.0% | |
| Q2 2025 | -5.3% | -6.5% | +32.5% | |
| Q1 2025 | +28.6% | +21.9% | -5.3% | |
| Q4 2024 | -1.0% | -5.9% | +1.0% | |
| Q3 2024 | +0.0% | -3.0% | -9.8% | |
| Q2 2024 | -5.4% | -7.0% | -31.7% | |
| Q1 2024 | +1.6% | +10.6% | +20.3% | |
| Q4 2023 | +4.2% | +1.8% | +8.1% | |
| Q3 2023 | +0.3% | -5.0% | -2.1% | |
| Q2 2023 | -8.0% | -1.7% | +13.0% | |
| Q1 2023 | -3.8% | +1.0% | -4.5% | |
| Q4 2022 | +24.8% | +21.1% | +7.1% | |
| Q3 2022 | -14.7% | -12.5% | -5.4% | |
| Q2 2022 | +0.7% | -4.5% | +2.1% | |
| Q1 2022 | +10.7% | +14.4% | +4.3% | |
| Q4 2021 | -14.5% | -17.7% | -45.1% | |
| Q3 2021 | -5.9% | +20.5% | +27.7% | |
| Q2 2021 | -2.2% | -6.2% | -5.8% | |
| Q1 2021 | +11.5% | +21.1% | +5.6% | |
| Q4 2020 | +1.0% | +8.2% | -2.0% | |
| Q3 2020 | +13.3% | +15.4% | +34.0% | |
| Q2 2020 | -2.0% | -2.9% | -28.0% | |
| Q1 2020 | -0.3% | -7.3% | +1.2% | |
| Q4 2019 | -22.7% | -29.7% | +1.0% | |
| Q3 2019 | +3.5% | -1.3% | -34.9% | |
| Q2 2019 | +2.8% | +0.0% | +2.8% | |
| Q1 2019 | -2.6% | -7.8% | -24.0% | |
| Q4 2018 | +19.0% | +37.3% | +45.2% | |
| Q3 2018 | -2.3% | -8.4% | -41.2% | |
| Q2 2018 | -6.1% | -10.1% | -12.2% | |
| Q1 2018 | +8.5% | +7.6% | +52.5% | |
| Q4 2017 | +2.7% | +3.4% | -11.0% | |
| Q3 2017 | -9.3% | -9.3% | +12.9% | |
| Q2 2017 | +1.9% | -2.5% | +35.6% | |
| Q1 2017 | -38.9% | -36.2% | -37.4% | |
| Q4 2016 | +9.0% | +11.9% | -5.2% | |
| Q3 2016 | +4.5% | +18.5% | +14.3% | |
| Q2 2016 | -1.9% | +3.8% | +41.8% | |
| Q1 2016 | -4.3% | — | — | |
| Q4 2015 | +0.7% | — | — | |
| Q3 2015 | +6.9% | — | — | |
| Q2 2015 | -3.2% | — | — | |
| Q1 2015 | -4.3% | — | — | |
| Q4 2014 | +5.1% | — | — | |
| Q3 2014 | -0.8% | — | — | |
| Q3 2013 | -0.8% | — | — | |
| Q2 2014 | +7.7% | — | — | |
| Q2 2013 | +7.7% | — | — | |
| Q1 2013 | +5.7% | — | — | |
| Q4 2013 | +5.7% | — | — | |
| Q1 2014 | +5.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro